TITLE

Sanofi-aventis Strikes Deal to Buy Genzyme

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p89
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the agreement reached by Sanofi-Aventis SA and Genzyme Corp. in which French drug maker Sanofi will acquire Genzyme for 20.1 billion U.S. dollars plus additional sum pegged to performance in Paris, France.
ACCESSION #
59994665

 

Related Articles

  • Sanofi Uses $21.2B Cash, CVR to Win Genzyme.  // Bioworld Week;2/21/2011, Vol. 19 Issue 8, p1 

    The article reports on the acquisition of Genzyme Corp. by French drug maker Sanofi-Aventis SA in a 20.1-billion dollar deal following a nine-month negotiation in the U.S. The takeover was made possible in Sanofi's second attempt after both parties decided to extend negotiations which cover the...

  • The Top 25 U.S. Pharmaceutical Manufacturing Companies.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p93 

    The article reports on the availability of a report entitled "The Top 25 U.S. Pharmaceutical Manufacturing Companies." Among the highlights the report include the nearly 8 billion dollars annual revenue of Gilead Sciences Inc., the acquisition of Genzyme Corp. by Sanofi-Aventis SA and the broad...

  • Sanofi-aventis to buy Ghattem.  // Chain Drug Review;1/4/2010, Vol. 32 Issue 1, p44 

    The article reports on the decision of French drug company Sanofi-Aventis SA to acquire drug developer Chattem Inc. of Chattanooga, Tennessee.

  • Sanofi makes cuts to field force, consolidates functions. Arnold, Matthew // Medical Marketing & Media;Dec2011, Vol. 46 Issue 12, p15 

    The article reports that Sanofi-Aventis SA will carry further reductions to its U.S. sales force and consolidation of several functions following its acquisition of Genzyme Corp.

  • Buyout Value Debate Goes on Despite Campath Data.  // Bioworld Week;10/18/2010, Vol. 18 Issue 42, p5 

    The article reports on the buyout value debate between Cambridge, Massachusetts-based biotech Genzyme Corp. and would acquirer Sanofi-Aventis SA on the 69 U.S. dollar-per-share increase proposal regardless of the data that proved the potential of alemtuzumab to treat multiple sclerosis (MS).

  • Another Genzyme Rejection as Sanofi Bid Turns 'Hostile'.  // Bioworld Week;10/18/2010, Vol. 18 Issue 42, p2 

    The article reports on the disapproval of Genzyme Corp.'s board of the 69 U.S. dollar- to 80 U.S. dollar-per-share offer of Sanofi-Aventis SA in Cambridge, Massachusetts.

  • Sanofi/Genzyme hostile. Ratner, Mark // Nature Biotechnology;Nov2010, Vol. 28 Issue 11, p1142 

    The article discusses the response of Genzyme on the tender offer made by Sanofi-aventis for 69 U.S. dollars per share.

  • sanofi Completes Genzyme Acquisition. Sutton, Stephanie // BioPharm International;May2011, Vol. 24 Issue 5, p12 

    The article reports on the acquisition of Sanofi-Aventis SA on Genzyme Corp. in the U.S. in 2011.

  • Genzyme, Sanofi Discuss Higher Buyout Price: Report.  // MondayMorning;1/10/2011, Vol. 19 Issue 1, p9 

    The article reports that stock prices of drug maker Genzyme Corp. increased by 4% in after-hours trading on January 7, 2011, after the publication of a report which says that French giant Sanofi-Aventis SA has offered a lucrative takeover bid to the company.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics